The present disclosure provides a medical adhesive and a preparation method thereof, comprising a component A and a component B: the component A comprises a cycloketene acetal compound and an oxidizing agent; the component B comprises a vinyl monomer, a cross-linking agent and a reducing agent, wherein the cycloketene acetal compound is selected from one or more of 2-methylene-1,3-dioxepane, 2-methylene-4-phenyl-1,3-dioxolane, 5,6-benzo-2-methylene-1,3-dioxepane and 4,7-dimethyl-2-methylene-1,3-dioxepane. The medical adhesive overcomes the disadvantages of conventional medical adhesives.

The present invention relates to an emulsion composition for chemoembolization comprising a nanoparticle comprising a drug and a biocompatible polymer, a water-soluble contrast agent and a water-insoluble contrast agent, and a water-insoluble drug as well as an aqueous drug can be administered in a form of stable emulsion, and drugs are slowly released, thereby enhancing the effect of chemoembolization.

This disclosure relates to pectin-based polymer compositions and methods of use thereof to cover, protect, and seal injuries, e.g., surgical wounds, in a mesothelial tissue. The methods include obtaining a bioadhesive pectin-based polymer composition including a complex of high-methoxyl pectin (HMP) and carboxymethylcellulose (CMC) in a ratio from about 10 to 1 to 1 to 10 by weight; applying the composition to an injured mesothelial tissue; and applying pressure for at least one minute to enable the composition to bind to the mesothelial tissue.

Compositions may include a therapeutic that is released from the composition to treat any number of ailments or conditions (e.g., pain, infection, cancer, osteoporosis) or to help accelerate local tissue regeneration (e.g., growth hormone, bone morphogenic protein) or to assist with surgical or therapeutic treatment (e.g., imaging modality), or any of a combination thereof.

The present disclosure provides a method for manufacturing a porous film, including: preparing a polymer mixture solution, wherein the polymer mixture solution includes polycaprolactone and at least one hydrophobic polymer; adding solid particles as a dispersing agent to the polymer mixture solution and mixing the solid particles with the polymer mixture solution, wherein the amount of solid particles added is enough to convert the polymer mixture solution into a solid mixture; drying the solid mixture to form a film; and washing the film with a washing fluid to remove the solid particles from the film to form the porous film, wherein the weight ratio of the polycaprolactone to the at least one hydrophobic polymer is about 1:0.1-10, and wherein the weight ratio of the polycaprolactone and the at least one hydrophobic polymer to the solid particles is about 1:0.01-250.

A water soluble biocompatible adhesive is provided comprising one or more compounds of structure 1 wherein B is an oligomer derived from a polyether or polyalkylene glycol, with a MW<5,000 g/mol, Linker L is a urethane, urea bond, or amide bond; Linker L′ is a urethane or urea bond, A is a chain extender of Mw≤3000 g/mol comprising substituted or unsubstituted alkyl, cycloalkyl and/or aromatic groups, W is a terminal adhesive benzene-1,2-diol derivative or a terminal adhesive benzene-1,2,3-diol derivative, m is 0 or 1; and n is 0, 1, 2, 3 or 4. The compound(s) have a Tg lower than 25° C. The biocompatible adhesive is suitable for use without solvent.

The present invention provides a biological tissue adhesive sheet having excellent tissue adhesiveness. The biological tissue adhesive sheet according to an embodiment of the present invention includes a nonwoven fabric made of fibers containing a crosslinked cold-water fish gelatin. Thereby, the biological tissue adhesive sheet according to the present invention is superior in tissue adhesiveness and film strength to conventional medical sheets.

The invention provides injectable, tough hydrogels that can be crosslinked in situ on demand using minimally-invasive methods, such as visible light exposure is an unmet medical challenge. Among the emerging biopolymers for tissue sealing, gelatin methacryloyl (GelMA), a naturally-derived biopolymer obtained from denatured collagen, has secured a promising role as a result of its excellent bioadhesion, biodegradation, and biocompatibility. To overcome one of the main shortcomings of GelMA, i.e., brittleness, we hybridized it using methacrylate-modified alginate (AlgMA) to impart ion-induced reversible crosslinking that can dissipate energy under strain. The hybrid GelMA-AlgMA hydrogels provide a photocrosslinkable, injectable, and adhesive platform with an excellent toughness that can be engineered using divalent cations, such as calcium. This class of novel hybrid biopolymers with more than 600% improved toughness may set the stage for durable, mechanically-resilient, and cost-effective tissue sealants in minimally invasive procedure, especially for stretchable tissues.

The present disclosure provides a biocompatible polymer, and the polymer includes the embolic microbead including an iron adsorption block capable of adsorbing an iron component. The embolic microbead according to the an exemplary embodiment of the present disclosure adsorbs iron and thus effectively blocks an iron component delivered to cancer cells, and when used in embolization, it has an improved effect in treating cancers, such as liver cancer.

Adhesives comprising rubber, tackifier, oil, and optionally absorbent and active ingredient are described. The adhesives are suitable for medical applications as they are repositionable on skin. Also described are medical articles using the adhesives.